Jeroen N Stoop - JoVE Visualize

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Annals of the Rheumatic Diseases|April 27, 2017

Breach of autoreactive B cell tolerance by post-translationally modified proteinsJacqueline S Dekkers, Marije K Verheul, Jeroen N Stoop, et al.

NPJ Vaccines|November 30, 2022

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaViki Bockstal, Maarten Leyssen, Dirk Heerwegh, et al.

Plos One|October 5, 2022

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled studyViki Bockstal, Georgi Shukarev, Chelsea McLean, et al.

Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Annals of the Rheumatic Diseases|April 27, 2017

Breach of autoreactive B cell tolerance by post-translationally modified proteinsJacqueline S Dekkers, Marije K Verheul, Jeroen N Stoop, et al.

NPJ Vaccines|November 30, 2022

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against EbolaViki Bockstal, Maarten Leyssen, Dirk Heerwegh, et al.

Plos One|October 5, 2022

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled studyViki Bockstal, Georgi Shukarev, Chelsea McLean, et al.

Pageof 3